**To:** Dartmouth Health Providers

**From:** Nancy M. Dunbar, MD, Blood Bank Medical Director

Brittany E. Condict, MLS(ASCP)CMSBBCM, Transfusion Medicine Service Manager

Rachael M. Chandler, MLT(ASCP)CMBBCM, Blood Bank Supervisor

**Date:** August 12, 2025

**Re:** Discontinuation ofRho(D) Immune Globulin (HyperRHO S/D) 50 mcg injection (MINI DOSE)

**Background:** Rho(D) Immune Globulin (HyperRHO S/D) 50 mcg injection (MINI DOSE) is an IM injection used to prevent anti-D sensitization in Rh negative pregnant women less than 12 weeks gestation.

Current obstetric guidelines are inconsistent with some recommending against Rh immunoglobulin administration before 12 weeks gestation due to very low risk of maternal Rh sensitization. As a result, demand for the mini dose has decreased significantly resulting in product loss due to expiration.

**Update:** Effective August 14, 2025 the Blood Bank will no longer be stocking the Rho(D) Immune Globulin (HyperRHO S/D) 50 mcg injection (MINI DOSE). When Rh immunoglobulin is clinically indicated, we recommend the Rho(D) Immune Globulin (HyperRHO S/D) 300 mcg injection (FULL DOSE) for all pregnant women regardless of gestational age.

**References:**

1. Horvath S, Goyal V, Traxler S, et al. Society of Family Planning committee consensus on Rh testing in early pregnancy. Contraception. 2022;114:1-5.
2. Prabhu M, Louis JM, Kuller JA, SMFM Publications Committee. Society for Maternal-Fetal Medicine Statement: RhD immune globulin after spontaneous or induced abortion at less than 12 weeks of gestation. Am J Obstet Gynecol. 2024;230(5):B2-B5.

**For questions or additional information, please contact:**

[Nancy.M.Dunbar@hitchcock.org](mailto:Nancy.M.Dunbar@hitchcock.org),[Brittany.E.Condict@hitchcock.org](mailto:Brittany.E.Condict@hitchcock.org),or[Rachael.M.Chandler@hitchcock.org](mailto:Rachael.M.Chandler@hitchcock.org)